What is MolecuLight?
MolecuLight specializes in the development and commercialization of point-of-care devices, such as the MolecuLight i:X and DX, which utilize fluorescence imaging to visualize bacterial presence in wounds. By integrating these diagnostic tools with electronic health records, the company enables healthcare professionals to make data-driven clinical decisions that significantly improve patient outcomes and accelerate healing rates. The company's technology addresses a critical gap in wound management, shifting the paradigm from subjective assessment to objective, evidence-based diagnostics. With FDA-cleared products, MolecuLight is well-positioned to capture a larger share of the global wound care market, leveraging its unique ability to provide immediate, non-invasive insights into wound health.
How much funding has MolecuLight raised?
MolecuLight has raised a total of $23.2M across 3 funding rounds:
Angel/Seed
$4M
Other Financing Round
$7.5M
Series C
$11.7M
Angel/Seed (2014): $4M with participation from iGan Partners
Other Financing Round (2019): $7.5M led by Oxford Finance
Series C (2024): $11.7M supported by Azahar Global Capital, Export Development Canada, and Prosegur
Key Investors in MolecuLight
iGan Partners
A prominent healthcare-focused venture capital firm based in Canada that partners with founders to commercialize and scale innovative medical solutions.
Azahar Global Capital
An investment firm dedicated to responsible capital allocation and sustainable development, focusing on strategic opportunities that generate positive societal impact.
Export Development Canada
A Canadian financial institution providing risk management, secure financing, and working capital services to support the growth of domestic companies.
What's next for MolecuLight?
With the successful closure of this major strategic investment, MolecuLight is poised to accelerate its global market penetration and enhance its product ecosystem. The capital will likely be deployed to scale manufacturing capabilities, expand sales and marketing operations, and further integrate its diagnostic platforms into hospital workflows across North America and beyond. As the company transitions into this mature growth phase, the focus will remain on clinical validation and the expansion of its digital health footprint. By leveraging its recent financing, MolecuLight aims to establish its fluorescence imaging technology as the standard of care, ultimately reducing the economic burden of chronic wounds on healthcare systems while improving the quality of life for patients worldwide.
See full MolecuLight company page
